Rallybio to Merge with Candid, Raises $505M and $700M Cash at Closing
Rallybio will merge with Candid Therapeutics, forming a Nasdaq-listed entity under ticker CDRX and securing over $505 million in private financing. The combined company will hold approximately $700 million pro-forma cash, fund operations through 2030, and existing Rallybio shareholders will own 3.65% post-closing.
1. Merger Agreement and Listing Plan
Rallybio has entered a definitive agreement to merge with Candid Therapeutics, creating a single Nasdaq-listed company under the new ticker CDRX. Both boards have unanimously approved the transaction, which is slated to close by mid-2026 pending shareholder and regulatory approvals.
2. Financing and Capital Structure
Candid secured over $505 million in a concurrent private financing round backed by institutional investors, boosting pro-forma cash to around $700 million at closing. The combined cash balance is projected to fund operations through 2030, with existing Rallybio shareholders owning 3.65% and Candid investors holding 96.35%.
3. Pipeline Advancement and Leadership
The merged entity will advance Candid’s T-cell engager portfolio, including Phase II initiation and data readouts for cizutamig targeting BCMA in myasthenia gravis and interstitial lung disease. Dr. Ken Song, Candid’s chairman and CEO, will lead the new company.